Published in Blood on March 15, 2002
Factor V Leiden in Chioggia: a prevalence study in patients with venous thrombosis, their blood relatives and the general population. Blood Transfus (2010) 1.03
VTE Risk assessment - a prognostic Model: BATER Cohort Study of young women. Thromb J (2005) 0.89
Flap complications and thrombophilia: an evidence-based model and cost analysis for preoperative screening. Eplasty (2011) 0.87
Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vasc Health Risk Manag (2007) 0.86
A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing. Genet Med (2015) 0.84
Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: a community-based cohort study. Thromb J (2005) 0.80
Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis (2016) 0.76
Budd-Chiari Syndrome in a Patient with JAK-2 V617F and Factor V G1691A Mutations. West Indian Med J (2014) 0.75
Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med (2012) 10.64
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med (2010) 5.65
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med (2004) 3.74
Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet (2007) 3.66
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51
An association between atherosclerosis and venous thrombosis. N Engl J Med (2003) 3.39
Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med (2008) 2.85
The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31
Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med (2003) 2.28
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09
X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med (2009) 2.02
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica (2007) 2.00
Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost (2008) 1.91
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood (2008) 1.90
A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J (2004) 1.80
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood (2009) 1.80
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood (2002) 1.78
The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation (2014) 1.64
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med (2007) 1.63
Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb Haemost (2006) 1.57
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. Thromb Haemost (2003) 1.46
A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med (2013) 1.42
Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. Blood (2013) 1.39
Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study. Blood (2013) 1.39
The association of a mild FXII deficiency with myocardial infarction and venous thrombosis is completely unjustified. J Thromb Thrombolysis (2009) 1.38
Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation (2008) 1.26
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood (2002) 1.23
Upper extremity deep venous thrombosis. Semin Thromb Hemost (2006) 1.14
Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost (2006) 1.12
Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost (2010) 1.11
Superficial vein thrombosis: risk factors, diagnosis, and treatment. Semin Thromb Hemost (2006) 1.11
Sex and anticoagulation in patients with idiopathic venous thromboembolism. Lancet (2006) 1.11
Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab (2002) 1.10
Simplification of the diagnostic management of suspected deep vein thrombosis. Arch Intern Med (2002) 1.09
The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica (2007) 0.98
Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. Eur J Cancer (2011) 0.97
The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. BMJ (2004) 0.96
C-reactive protein in hypertensive disorders in pregnancy. Clin Appl Thromb Hemost (2006) 0.95
An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood (2002) 0.93
The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. Thromb Haemost (2002) 0.93
Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica (2007) 0.93
Rebuttal: factor XII levels, factor XII 46 C>T polymorphism and venous thrombosis: a word of caution is needed. Thromb Haemost (2004) 0.92
Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts. Transplantation (2005) 0.89
ABO blood groups and the risk of venous thrombosis in patients with inherited thrombophilia. Blood Transfus (2012) 0.89
Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med (2002) 0.89
Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation (2011) 0.89
Cancer Screening in Unprovoked Venous Thromboembolism. N Engl J Med (2015) 0.89
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res (2011) 0.89
Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost (2013) 0.88
Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. Thromb Haemost (2010) 0.87
Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants. Thromb Res (2006) 0.86
Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist (2005) 0.86
Fainting induces an acute increase in the concentration of plasma factor VIII and von Willebrand factor. Haematologica (2003) 0.86
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost (2015) 0.85
Thrombophilia as a predictor of persistent residual vein thrombosis. Haematologica (2008) 0.85
An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood (2005) 0.85
Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med (2011) 0.84
Safety of dental extraction among consecutive patients on oral anticoagulant treatment managed using a specific dental management protocol. Blood Coagul Fibrinolysis (2003) 0.84
The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost (2003) 0.84
Does hemophilia protect against atherosclerosis? A case-control study. Clin Appl Thromb Hemost (2006) 0.83
Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica (2005) 0.83
The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica (2006) 0.83
Double vena cava filter insertion in congenital duplicated inferior vena cava: a case report and literature review. Haematologica (2006) 0.83
Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res (2009) 0.83
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. Thromb Haemost (2014) 0.82
The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood (2002) 0.82
Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood (2010) 0.82
Heart disease in patients with pulmonary embolism. Curr Opin Pulm Med (2010) 0.82
Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism. Thromb Haemost (2004) 0.82
In vitro and in vivo effects of the carbon monoxide-releasing molecule, CORM-3, in the xenogeneic pig-to-primate context. Xenotransplantation (2009) 0.81
Genetic study in patients with factor XII deficiency: a report of three new mutations exon 13 (Q501STOP), exon 14 (P547L) and -13C>T promoter region in three compound heterozygotes. Blood Coagul Fibrinolysis (2008) 0.81
Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood (2002) 0.81
Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population. Thromb Haemost (2005) 0.81
Recurrent venous thromboembolism in men and women. N Engl J Med (2004) 0.81
Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res (2009) 0.81
The postthrombotic syndrome. Intern Emerg Med (2009) 0.81
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study. Haematologica (2007) 0.80
Elastic stockings, hydroxyethylrutosides or both for the treatment of post-thrombotic syndrome. Thromb Haemost (2005) 0.80
High prevalence of inherited thrombophilia in 'presumed peri-neonatal' ischemic stroke. Eur J Haematol (2007) 0.80
Inherited thrombophilia and venous thromboembolism. Semin Thromb Hemost (2006) 0.80